187039-57-2

Basic information

• Product Name: BOC-(2S,3S)-3-HYDROXYPYRROLIDINE-2-CARBOXYLIC ACID
• Synonyms: BOC-TRANS-3-HYDROXY-L-PROLINE;BOC-(2S,3S)-3-HYDROXY-2-PYRROLIDINECARBOXYLIC ACID;BOC-(2S,3S)-3-HYDROXYPYRROLIDINE-2-CARBOXYLIC ACID;(2S,3S)-1-(TERT-BUTOXYCARBONYL)-3-HYDROXYPYRROLIDINE-2-CARBOXYLIC ACID;1,2-Pyrrolidinedicarboxylicacid, 3-hydroxy-, 1-(1,1-diMethylethyl) ester, (2S,3S)-;(2S,3S)-3-Hydroxy-1,2-pyrrolidinedicarboxylic acid 1-(1,1-dimethylethyl) ester;( 2S, 3S)-3-hydroxy-pyrrolidine-1,2-dicarboxylic acid tert butyl ester
• CAS NO: 187039-57-2
• Molecular Formula: C₁₀H₁₇NO₅
• Molecular Weight: 231.25
• Mol File: 187039-57-2.mol

Chemical Properties

• Melting Point: 157℃
• Boiling Point: 390.9 °C at 760 mmHg
• Flash Point: 190.2 °C
• Appearance: /
• Density: 1.312±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: 2-8°C
• PKA: 3.69±0.40(Predicted)
• CAS DataBase Reference: BOC-(2S,3S)-3-HYDROXYPYRROLIDINE-2-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-(2S,3S)-3-HYDROXYPYRROLIDINE-2-CARBOXYLIC ACID(187039-57-2)
• EPA Substance Registry System: BOC-(2S,3S)-3-HYDROXYPYRROLIDINE-2-CARBOXYLIC ACID(187039-57-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 187039-57-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
BOC-(2S,3S)-3-HYDROXYPYRROLIDINE-2-CARBOXYLIC ACID is used as an intermediate compound for the synthesis of drugs that target neurological and psychological disorders. Its unique stereochemistry and molecular structure make it a valuable component in the development of new therapeutic agents.
Used in Drug Synthesis:
In the pharmaceutical industry, BOC-(2S,3S)-3-HYDROXYPYRROLIDINE-2-CARBOXYLIC ACID is used as a building block in the synthesis of various drugs. Its presence in the molecular structure of these drugs contributes to their efficacy in treating specific neurological and psychological conditions.
Used in Research Laboratories:
BOC-(2S,3S)-3-HYDROXYPYRROLIDINE-2-CARBOXYLIC ACID is also used in research laboratories for studying the properties and potential applications of pyrrolidine-based compounds. Its stereochemistry and molecular structure provide insights into the design and synthesis of novel drug candidates.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 567-36-2 3-hydroxypyrrolidine-2-carboxylic acid 
• 184046-78-4 (2S,3S)-1-tert-butyl-2-methyl 3-hydroxypyrrolidine-1,2-dicarboxylate 
• 34619-03-9 tert-butyldicarbonate 
• 4298-08-2 trans-3-hydroxy-L-proline 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 
• 14916-76-8 trans-3-Hydroxy-(L)-proline 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 

Downstream Products

• 187039-58-3 (2S,3S)-2-Benzyloxycarbamoyl-3-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1310585-36-4 4-[3,3-dimethyl-2-(2-methylamino-propionylamino)-butyryl]-3-[2-(4-fluoro-phenylamino)-thiazol-4-yl]-octahydro-pyrrolo[3,2-b]pyrrole-1-carboxylic acid benzyl ester 
• 1310585-80-8 4-{2-[2-(tert-butoxycarbonyl-methyl-amino)-propionylamino]-3,3-dimethyl-butyryl}-3-[2-(4-fluoro-phenylamino)-thiazol-4-yl]-octahydro-pyrrolo[3,2-b]pyrrole-1-carboxylic acid benzyl ester 
• 1310585-79-5 4-(2-amino-3,3-dimethyl-butyryl)-3-[2-(4-fluoro-phenylamino)-thiazol-4-yl]-octahydro-pyrrolo[3,2-b]pyrrole-1-carboxylic acid benzyl ester 
• 1310585-78-4 4-(2-tert-butoxycarbonylamino-3,3-dimethyl-butyryl)-3-[2-(4-fluoro-phenylamino)-thiazol-4-yl]-octahydro-pyrrolo[3,2-b]pyrrole-1-carboxylic acid benzyl ester 
• 1310585-77-3 3-[2-(4-fluoro-phenylamino)-thiazol-4-yl]-octahydro-pyrrolo[3,2-b]pyrrole-1-carboxylic acid benzyl ester 
• 1310585-76-2 {1-[4-cyclopropanecarbonyl-6-(8-phenyl-imidazo[1,2-a]pyridin-2-yl)-octahydro-pyrrolo[3,2-b]pyrrole-1-carbonyl]-2,2-dimethyl-propyl}-carbamic acid tert-butyl ester 
• 1310585-75-1 {1-[4-isopropylcarbamoyl-6-(8-phenyl-imidazo[1,2-a]pyridin-2-yl)-octahydro-pyrrolo[3,2-b]pyrrole-1-carbonyl]-2,2-dimethyl-propyl}-carbamic acid tert-butyl ester 
• 1310585-33-1 N-{1-[4-methanesulfonyl-6-(8-phenyl-imidazo[1,2-a]pyridin-2-yl)-octahydro-pyrrolo[3,2-b]pyrrole-1-carbonyl]-2,2-dimethyl-propyl}-methylamino-propionamide 
• 1310585-74-0 (1-{1-[4-methanesulfonyl-6-(8-phenyl-imidazo[1,2-a]pyridin-2-yl)-octahydro-pyrrolo[3,2-b]pyrrole-1-carbonyl]-2,2-dimethyl-propylcarbamoyl}-ethyl)-methyl-carbamic acid tert-butyl ester 
• 1310585-73-9 2-amino-1-[4-methanesulfonyl-6-(8-phenyl-imidazo[1,2-a]pyridin-2-yl)-octahydro-pyrrolo[3,2-b]pyrrole-1-carbonyl]-3,3-dimethyl-butan-1-one 
• 1310585-72-8 {1-[4-methanesulfonyl-6-(8-phenyl-imidazo[1,2-a]pyridin-2-yl)-octahydro-pyrrolo[3,2-b]pyrrole-1-carbonyl]-2,2-dimethyl-propyl}-carbamic acid tert-butyl ester 
• 1310585-71-7 {2,2-dimethyl-1-[6-(8-phenyl-imidazo[1,2-a]pyridin-2-yl)-octahydro-pyrrolo[3,2-b]pyrrole-1-carbonyl]-propyl}-carbamic acid tert-butyl ester 
• 1310585-70-6 4-(2-tert-butoxycarbonylamino-3,3-dimethyl-butyryl)-3-(8-phenyl-imidazo[1,2-a]pyridin-2-yl)-octahydro-pyrrolo[3,2-b]pyrrole-1-carboxylic acid benzyl ester 

Relevant articles and documents

PCSK9 ANTAGONIST COMPOUNDS

Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt thereof: (I) wherein A, A1, A2, R1, R2 and R3 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

PCSK9 ANTAGONIST BICYCLO-COMPOUNDS

Disclosed are compounds of Formula I, or a salt thereof cyclic polypeptide of Formula I: Formula I where A, B, E, R4, and R8 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceut

CONFORMATIONALLY CONSTRAINED MACROCYCLIC COMPOUNDS

Conformationally constrained macrocyclic compounds of formula (I), including substituents E with at least one ester moiety, G and Q, as defined in the description and the claims, and salts thereof, can be metabolized to compounds that have the property to

DIFLUOROPYRROLIDINES AS OREXIN RECEPTOR MODULATORS

The present application relates to certain difluoropyrrolidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.

THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF

The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

ANTI-VIRAL COMPOUNDS

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Novel tricyclic pyrazolopyrimidines as potent and selective GPR119 agonists

Systematic SAR optimization of the GPR119 agonist lead 1, derived from an internal HTS campaign, led to compound 29. Compound 29 displays significantly improved in vitro activity and oral exposure, leading to GLP1 elevation in acutely dosed mice and reduc

Chemoselective synthesis of N-protected alkoxyprolines under specific solvation conditions

N-Protected hydroxyprolines (Hyp) were transformed chemoselectively into alkoxyproline derivatives by direct O-alkylation. The starting Hyp was transformed into the corresponding dianion in a mixture of dimethyl sulfoxide and tetrahydrofuran (1:16 v/v) as solvent. Under these conditions, the carboxy-anion showed reduced nucleophilicity because it was specifically solvated, and the more reactive oxy-anion was selectively alkylated. N-Protected trans-4-alkoxy-, cis-4-alkoxy- and trans-3-alkoxyprolines were thus obtained in a single step in very high overall yields and with complete stability of the stereogenic center configuration. Copyright

N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY

Described herein are N-hydroxyamlde antibacterial compounds, methods for making the compounds, pharmaceutical compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical compositions compound of Formula (I): or a salt, solvate ti hydrate thereof, wherein A is (a) eachindicates a point of attachment.

Anti-Viral Compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.